This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Quotient Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Manuel Mendez

Chief executive officer

US$16.2m

Total compensation

CEO salary percentage	5.0%
CEO tenure	2.2yrs
CEO ownership	0.06%
Management average tenure	1.8yrs
Board average tenure	no data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Manuel Mendez's remuneration changed compared to Quotient's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	-US$124m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	US$16m	US$810k	-US$125m

Compensation vs Market: Manuel's total compensation ($USD16.22M) is above average for companies of similar size in the German market ($USD410.36K).

Compensation vs Earnings: Insufficient data to compare Manuel's compensation with company performance.

CEO

Manuel Mendez (55 yo)

2.2yrs

Tenure

US$16,217,915

Compensation

Mr. Manuel O. Mendez had been Senior Vice President and Chief Commercial Officer of Quest Diagnostics Incorporated since October 7, 2019 until February 22, 2021. He had been Senior Vice President of Global...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Manuel Mendez	CEO & Director	2.2yrs	US$16.22m	0.057% $ 1.5k
Ali Kiboro	Chief Financial Officer	1.6yrs	US$1.65m	0.015% $ 383.0
Mohammad El Khoury	Chief Commercial Officer	1.7yrs	US$1.87m	0.024% $ 600.3
Vittoria Bonasso	Head of Finance	2.3yrs	no data	0.0019% $ 46.7
Michael Hausmann	Chief Technology Officer	1.8yrs	no data	no data
Christine Ginocchio	Chief Scientific & Medical Officer	1.7yrs	no data	no data
Viviane Montarnal	Head of Legal Affairs & Compliance	3.2yrs	no data	no data
Christian Albrich	Chief People Officer	1.8yrs	no data	no data
Esteban Uriarte	Chief Manufacturing Operations Officer	1.3yrs	no data	no data
Steven Zuiderwijk	Chief Strategy & Business Development Officer	less than a year	no data	no data
Michael Campbell	Head of Regulatory Affairs & Quality	4.3yrs	no data	no data

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: U4W0's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

This company listing is no longer active

Quotient Management

Management criteria checks 0/4

Key information

Recent management updates

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Announces Resignation of Franz Walt as Director

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Recent updates

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought €140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings released: US$0.37 loss per share (vs US$0.27 loss in 1Q 2022)

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$1.23 loss per share (vs US$1.18 loss in FY 2021)

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought €70k worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought €91k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

New 90-day low: €3.90

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

Chief Commercial Officer recently sold €129k worth of stock

New 90-day low: €4.06

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

New 90-day high: €5.30

Second quarter 2021 earnings released: US$0.18 loss per share

Revenue beats expectations

Quotient Limited to Report Q2, 2021 Results on Nov 02, 2020

Quotient Limited Receives Receipt of U.S. FDA Emergency Use Authorization or Mosaiq COVID19 Antibody Test

Quotient Limited has completed a Follow-on Equity Offering in the amount of $75.000001 million.

New 90-day low - €4.54

New 90-day low - €5.60

Earnings released

Quotient Limited to Report Q1, 2021 Results on Aug 03, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age